Absstract of: WO2021255480A1

The present invention provides for a modified autotransporter and the use of genetically engineered microorganisms comprising said modified autotransporters in the treatment of infectious and neoplastic disease. The present invention therefore also relates to vaccine and immunotherapeutic compositions comprising said genetically engineered microorganism.

Absstract of: WO2021255684A1

A composition comprising Shigella-Tetravalent (4-valent Shigella) bioconjugates. That encompasses the Shigella O-polysaccharide antigens of serotypes Shigella flexneri 2a, 3a, 6 and Shigella sonnei covalently linked to the protein carrier.

Absstract of: WO2023063933A1

The present invention is a physical pathogen reduction method and apparatus for controlling or eliminating transfusion-transmittable infections. This purely physical technique does not involve the use of heat, chemicals and/or irradiation, each of which has significant drawbacks in the pathogen reduction of human plasma, The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in units of human plasma, while retaining the natural biological activity, integrity and potency of the treated plasma. The method uses critical, near-critical or supercritical fluids for viral and pathogen reduction of units of donor blood plasma, using novel blood plasma bags. The apparatus is in the form of a bench-top or mobile transportable unit, which can be used in hospitals, blood banks, medical facilities and hot zones in developing countries for the clearance of viruses from human plasma.

Absstract of: US2023122752A1

The present invention relates to a synthetic saccharide of general formula (I) that is related to Klebsiella pneumoniae serotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistant Klebsiella pneumoniae ST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae bacteria.

Absstract of: US2023123485A1

Provided are microbial compositions comprising at least one attenuated form of a pathogenic bacterium having an ability to colonize at least one organ of the gastrointestinal tract of an animal, such as an attenuated form of a bacterium having an antagonistic effect against a bacterium selected from the group consisting of Salmonella enteritidis, Salmonella enterica, Salmonella typhimurium, lostridium difficile, Clostridium perfringens, Escherichia coli, Campylobacter spp., Listeria monocytogenes, Yersinia enterocolitica and combinations thereof. Also provided are animal feeds comprising such compositions, preparations for in-ovo injection comprising such compositions and methods of treatment using such compositions.

Absstract of: US2023121528A1

The present invention relates to a Salmonella typhi Ty21a strain comprising a DNA molecule comprising at least one eukaryotic expression cassette encoding at least one tumor antigen, stroma antigen and/or checkpoint inhibitor antigen for the use in the treatment of cancer in a human subject following treatment with an antibiotic, wherein the Salmonellatyphi Ty21a strain is to be administered orally and optionally in combination with a checkpoint inhibitor.

Absstract of: WO2021178888A1

The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein the Salmonella Typhi vector has been engineered to express one or more cancer antigens. In some aspects the vector has been engineered to express an outer membrane folding protein Bam A or a fragment or variant thereof; and a lipid A deacylase PagL or a fragment or variant thereof, wherein the Salmonella Typhi vector is capable of delivering the antigen to a mucosal tissue or subcutaneously to dendritic cells via an outer membrane vesicle when administered to a subject.

Absstract of: WO2021178891A1

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein the Salmonella Typhi vector has been engineered to express one or more antigens; an outer membrane folding protein Bam A or a fragment or variant thereof; and a lipid A deacylase PagL or a fragment or variant thereof, wherein the Salmonella Typhi vector is capable of delivering the antigen to a mucosal tissue via an outer membrane vesicle when administered to a subject.

Absstract of: WO2016115097A2

The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.

Absstract of: WO2016115097A2

The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.

Absstract of: US2017198297A1

The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of heterologous proteins into eukaryotic cells.

Absstract of: WO2023060081A1

The present disclosure describes a self-sprayer device for self-administering an animal product to an animal and providing environmental enrichment to the animal.

Absstract of: WO2017168742A1

This microorganism identification method comprises: a step in which a sample containing microorganisms is subjected to mass spectrometry and a mass spectrum is obtained; a reading step in which the mass-to-charge ratio m/z of peaks derived from a marker protein is read from the mass spectrum; and an identification step in which the mass-to-charge ratio m/z is used as a basis to identify whether the microorganisms included in the sample include any bacterial species from among Escherichia coli, bacteria of the genus Shigella, and Escherichia albertii. The microorganism identification method is characterized in that at least one of the following thirteen types of ribosomal proteins is used as the marker protein: S5; L15; S13; L31; L22; L19; L20; L13; S15; L25; HNS; HdeB; and L29.

Absstract of: US2023105761A1

The present disclosure describes a self-sprayer device for self-administering an animal product to an animal and providing environmental enrichment to the animal.

Absstract of: US2023104907A1

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector, wherein the Salmonella typhi vector has been engineered to express one or more antigens; an outer membrane folding protein Barn A or a fragment or variant thereof; and a lipid A deacylase PagL or a fragment or variant thereof, wherein the Salmonella typhi vector is capable of delivering the antigen to a mucosal tissue via an outer membrane vesicle when administered to a subject.

Absstract of: EP4159746A1

The present invention relates to a chimeric recombinant protein having a therapeutic effect on cervical cancer by fusing genetic modified E6 and E7, which are carcinogenesis-inducing proteins of human papillomavirus high-risk group type 16, with a fusion protein for increasing immunogenicity, the HPV type 16 E6, E7 chimeric recombinant protein fused with the flagellin fusion protein of the present invention showed the lowest tumor cell volume, and the immune response of specific T cells according to the recombinant antigen was significantly confirmed, and when the prophylactic effect was measured, it was confirmed that the volume of tumor cells was low and the antibody titer was increased, therefore human papillomavirus recombinant antigen of the present invention shows tumor treatment and prophylaxis and can be applied as a therapeutic/prophylactic vaccine composition.

Absstract of: KR102327091B1

The present invention relates to a Salmonella strain selectively acting on cancer to treat cancer and a composition for preventing or treating cancer, comprising the same. Specifically, the Salmonella strain according to the present invention has a tumor-suppressing effect, and has remarkably low viability in a normal organ, thereby having a remarkable anticancer effect compared to the conventional inventions.

Absstract of: CN115873930A

The invention discloses a double-target detection method for drug-resistant salmonella based on RPA-Cas12a, which comprises the following steps: culturing the drug-resistant salmonella overnight, cleaning, heating, cracking, centrifugally extracting supernatant, placing a DNA (deoxyribonucleic acid) extracting solution, RPA (recombinase polymerase amplification) freeze-dried powder, a primer and a buffer solution required by RPA amplification at the bottom of an Ep tube with a tube cover, and temporarily storing a Cas12a detection solution in the tube cover; then, the Ep tube is flatly placed, and after amplification, Cas12a detection liquid in a tube cover flows to the tube bottom in a transient centrifugation mode and is mixed with amplification liquid at the tube bottom; and after the Ep tube is continuously incubated for a period of time, carrying out fluorescence detection on a reaction product. The Cas12a is placed in the cover of the Ep tube, after RPA in the Ep tube reacts, the Cas12a is added in a centrifugal mode, salmonella detection can be achieved in a short time, the detection sensitivity is high, operation is more convenient, and cross contamination between samples is avoided.

Absstract of: CN115873704A

The salmonella drug resistance detection device comprises a box body and a bearing disc used for bearing drug sensitive paper sheets, and a positioning mechanism used for positioning the bearing disc and a grabbing mechanism used for grabbing the drug sensitive paper sheets on the bearing disc to a culture dish are arranged in the box body; during an experiment, the drug sensitive paper sheets are placed on the bearing plates, the plurality of bearing plates are positioned through the positioning mechanism, the grabbing mechanism grabs the drug sensitive paper sheets into the culture dish, the drug sensitive paper sheets can be automatically attached to the surface of a culture medium, manual clamping is not needed, the experiment efficiency is improved, and the pollution risk is reduced.

Absstract of: EP4155414A1

The present disclosure provides an insertion and deletion (InDel) molecular marker of a hisD gene of ultrasonically-mutagenized Salmonella typhimurium (S. typhimurium) and use thereof, and belongs to the field of molecular biology. In the present disclosure, through ultrasonic mutagenesis to S. typhimurium and sequencing, it is found that all InDel mutations occur in a core mutation region of the hisD gene. Therefore, the core mutation region is used as the InDel molecular marker to determine an insertion or a deletion of a gene reverse mutation, and the InDel molecular marker can also be used to analyze a relationship between a sequence of the hisD gene and a function of a protein encoded thereby.

Absstract of: CN115850407A

The invention belongs to the technical field of germ detection, and particularly relates to an antigen protein and application thereof, and the antigen protein is suitable for salmonella pullorum detection. The antigen protein comprises a sequence as shown in SEQIDNO.1 or SEQIDNO.2, the antigen protein has very strong specificity to salmonella pullorum antibodies, the salmonella pullorum is detected by an indirect ELISA (Enzyme-Linked Immunosorbent Assay) method taking the two antigen proteins as coating antigens, the minimum positive serum dilution ratio can reach 1: 1600, and the sensitivity is high; in addition, the intra-batch repetition variable coefficient and the inter-batch repetition variable coefficient are both lower than 10%, and repeatability is good.

Absstract of: CN115851771A

The invention discloses a salmonella gallinarum attenuated isolated strain not expressing Peg mycosis and application of the salmonella gallinarum attenuated isolated strain. The isolated strain is orally inoculated with an SGOP strain with the dose of 1 * 10 < 10 > CFU and has no pathogenicity to SPF chickens of 1 day age, the SGOP strain is immunized and inoculated to the SPF chickens of 1 day age, chicken flocks immunized with the SGOP strain can resist toxic attack of salmonella gallinarum wild strain U20 after 21 days, and 70% of chicken flocks attacked with toxic attack are protected without diseases. The SGOP strain disclosed by the invention is relatively high in safety, does not influence the monitoring and purification procedures of avian salmonella, and has relatively great potential in clinical prevention and control of salmonella gallinarum infection and marker attenuated vaccine candidate strains thereof.

Absstract of: CN115851988A

The invention relates to the technical field of microbiological detection, and particularly discloses a multiple PCR detection primer combination for bacteria and application thereof, and the multiple PCR detection primer combination for bacteria comprises primer combinations for performing multiple PCR detection on pseudomonas aeruginosa, staphylococcus aureus, klebsiella pneumoniae, proteus mirabilis, helicobacter and salmonella respectively. The invention also provides a multiple PCR detection kit for bacteria and a multiple PCR detection method for bacteria. The detection primer combination disclosed by the invention has good sensitivity and specificity, is matched with an optimized amplification system and program, so that the amplification efficiency is remarkably improved, the result is accurate, the efficiency is high, the consumed time is short, the damage to animals can be avoided, and the detection primer combination has a practical application value.

Absstract of: CN115856297A

The invention provides a preparation method of a kit for detecting salmonella typhimurium and the kit, and belongs to the technical field of kits. The preparation method comprises the following steps: firstly, preparing magnetic beads with superparamagnetism, coating the magnetic beads serving as a magnetic core with an organic covalent skeleton (COF) to form a core-shell structure, namely MCOF nano magnetic particles, and then loading gold nanoparticles on the MCOF nano magnetic particles by using an in-situ reduction method, so as to obtain the MCOF nano magnetic particles. And finally, coupling with an aptamer of salmonella typhimurium to synthesize the nano probe apt-MCOF-AuNPs with high fluorescence emission. The salmonella typhimurium and the nanoprobe are co-incubated to form a probe-thallus compound, a quenching agent Fe < 3 + > is added to quench fluorescence of the probe, the fluorescence of the probe cannot be quenched by the Fe < 3 + > due to the protective effect of thallus on the nanoprobe and competitive binding of the thallus and the Fe < 3 + >, and the solution is bright green fluorescence under irradiation of 365 nm ultraviolet light. Therefore, rapid and specific detection of salmonella typhimurium is realized.

Absstract of: CN115844955A

The invention belongs to the technical field of traditional Chinese veterinary medicines, and particularly relates to a traditional Chinese veterinary medicine'alternative resistance 'compound preparation as well as a preparation method and application thereof. The traditional Chinese veterinary medicine'anti-replacement 'compound preparation is prepared from the following raw materials in parts by weight: 10 to 20 parts of flos lonicerae extract, 20 to 40 parts of macleaya cordata extract, 10 to 20 parts of radix scutellariae extract, 10 to 20 parts of radix astragali seu hedysari extract, 5 to 20 parts of herba lysimachiae extract and 5 to 20 parts of cassia twig extract. The traditional Chinese veterinary medicine'anti-replacement 'compound preparation provided by the invention can effectively prevent common pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella and pasteurella in the chicken breeding process. The method has important research value in the field of traditional Chinese veterinary medicines, improves the green breeding level of China, and ensures food safety.